Tier 3 — preclinical

Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3

Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsström S, Pasila L, Velagapudi V, Carroll CJ, Auwerx J, Suomalainen A

EMBO molecular medicine 2014 6; 6; 721-731

Bibliography

PubMed: PMID 24711540
PubMed Central: PMC4203351
DOI: 10.1002/emmm.201403943
Funding: European and Finnish public, university and charitable research support, including ERC, Academy of Finland, NIH and Swiss research programs.
Competing interests: A complete competing-interest declaration is not specified in the accessible publication information.

Design	Preclinical animal study with supporting assays as applicable
Model	Mice with mitochondrial myopathy
Sample	Mitochondrial-myopathy mouse experiments
Intervention	Oral NR
Duration	Early- and late-stage disease treatment protocols
Endpoints	Model-specific physiological outcomes; Biochemical or functional measures reported in the study

NR improved mitochondrial biogenesis and selected disease features in a mouse model of mitochondrial myopathy.

NR improved mitochondrial biogenesis and selected disease features in a mouse model of mitochondrial myopathy.

A disease-model experiment does not establish efficacy across genetically diverse human mitochondrial disorders.

Editorial review

Last verified 22 October 2026